Yan Wang

Yan Wang has a diverse work experience in the fields of bioanalytical development, pharmacokinetics, and drug metabolism. They have held various roles throughout their career, including Director of Bioanalytical Development at Halozyme Therapeutics, where they led and managed contract research organizations and implemented bioanalytical strategies in support of clinical development programs. Prior to that, Yan worked as a Scientist IV at Dart NeuroScience, where they led the bioanalytical group and provided LC-MS method development/validation, pharmacokinetics, and toxicokinetics studies. They also have experience as a Principle Scientist at Regulus Therapeutics and a Senior Investigator at Amylin Pharmaceuticals, where they conducted quantification analysis, developed analytical methods, and supported pharmacokinetic studies using mass spectrometry techniques. Before their industry experience, Yan worked as a Postdoctoral Research Associate at TMRI, Syngenta, where they conducted research on genome-wide characterization of rice transcription factors binding sites. Overall, Yan has a strong background in bioanalytical development and pharmacokinetics, with expertise in various techniques such as mass spectrometry and protein-binding assays.

Yan Wang holds a Ph.D. degree in Molecular Biology and Biochemistry from Uppsala University in Sweden. No specific years of attendance or completion are mentioned.